NCT02383368View on ClinicalTrials.gov

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions

LymphomaRefractory Solid TumorsAdvanced Cancer

Interventions

DRUG

ASP4132

oral

Trial Locations (5)

22031

Site US10005, Fairfax

55905

Site US10002, Rochester

60637

Site US10004, Chicago

77030

Site US10003, Houston

06520

Site US10001, New Haven

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02383368 - A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma | Biotech Hunter | Biotech Hunter